📇 Rhumatologue · LE CHESNAY CEDEX · (78) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
86.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CH DE VERSAILLES SITE ANDRE MIGNOT
177 R DE VERSAILLES, 78157 LE CHESNAY CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
Purpose Comprehensive geriatric assessment (CGA) is recommended to assess the vulnerability of elderly patients, but its integration in cancer treatment decision making has never been prospectively evaluated. Here, in elderly patients with advanced non–small-cell lung cancer (NSCLC), we compared a standard strategy of chemotherapy allocation on the basis of performance status (PS) and age with an experimental strategy on the basis of CGA. Patients and Methods In a multicenter, open-label, phase III trial, elderly patients ≥ 70 years old with a PS of 0 to 2 and stage IV NSCLC were randomly assigned between chemotherapy allocation on the basis of PS and age (standard arm: carboplatin-based doublet if PS ≤ 1 and age ≤ 75 years; docetaxel if PS = 2 or age > 75 years) and treatment allocation on the basis of CGA (CGA arm: carboplatin-based doublet for fit patients, docetaxel for vulnerable patients, and best supportive care for frail patients). The primary end point was treatment failure free survival (TFFS). Secondary end points were overall survival (OS), progression-free survival, tolerability, and quality of life. Results Four hundred ninety-four patients were randomly assigned (standard arm, n = 251; CGA arm, n = 243). Median age was 77 years. In the standard and CGA arms, 35.1% and 45.7% of patients received a carboplatin-based doublet, 64.9% and 31.3% received docetaxel, and 0% and 23.0% received best supportive care, respectively. In the standard and CGA arms, median TFFS times were 3.2 and 3.1 months, respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.1), and median OS times were 6.4 and 6.1 months, respectively (hazard ratio, 0.92; 95% CI, 0.79 to 1.1). Patients in the CGA arm, compared with standard arm patients, experienced significantly less all grade toxicity (85.6% v 93.4%, respectively P = .015) and fewer treatment failures as a result of toxicity (4.8% v 11.8%, respectively; P = .007). Conclusion In elderly patients with advanced NSCLC, treatment allocation on the basis of CGA failed to improve the TFFS or OS but slightly reduced treatment toxicity.
Lung cancer (Amsterdam, Netherlands) · 2014
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of thoracic disease · 2017 · Journal Article
Le Caer H, Borget I, Corre R, Locher C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · Clinical Trial, Phase III
Corre R, Greillier L, Le Caër H, Audigier-Valette C, et al.
BMC cancer · 2014 · Clinical Trial, Phase II
Lerouge D, Rivière A, Dansin E, Chouaid C, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.
Journal of thoracic disease · 2017 · Journal Article
Le Caer H, Borget I, Corre R, Locher C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016 · Clinical Trial, Phase III
Corre R, Greillier L, Le Caër H, Audigier-Valette C, et al.
Bulletin du cancer · 2019 · Comparative Study
Debieuvre D, Locher C, Asselain B, Dayen C, et al.
Lung cancer (Amsterdam, Netherlands) · 2014 · Journal Article
Chouaid C, Dujon C, Do P, Monnet I, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.
Clinical lung cancer · 2013 · Clinical Trial, Phase II
Chouaid C, Le Caer H, Corre R, Crequit J, et al.
BMC cancer · 2012 · Clinical Trial, Phase II
Chouaid C, Le Caer H, Locher C, Dujon C, et al.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2011 · Clinical Trial, Phase III
Vergnenegre A, Corre R, Berard H, Paillotin D, et al.